Publication:
Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

dc.contributor.buuauthorAtasayar, Gülfer
dc.contributor.buuauthorEryılmaz, Işıl Ezgi
dc.contributor.buuauthorKarlı, Necdet
dc.contributor.buuauthorEgeli, Ünal
dc.contributor.buuauthorZarifoğlu, Mehmet
dc.contributor.buuauthorÇeçener, Gülşah
dc.contributor.buuauthorTaşkapılıoğlu, Özlem
dc.contributor.buuauthorTunca, Berrin
dc.contributor.buuauthorYıldırım, Öznur
dc.contributor.buuauthorAk, Seçil
dc.contributor.buuauthorTezcan, Gülçin
dc.contributor.buuauthorCan, Fatma Ezgi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Biyoloji Ana Bilim Dalı
dc.contributor.departmentNöroloji Ana Bilim Dalı
dc.contributor.departmentBiyoistatistik Ana Bilim Dalı
dc.contributor.orcid0000-0002-1619-6680
dc.contributor.orcid0000-0002-3820-424X
dc.contributor.orcid0000-0002-3316-316X
dc.contributor.orcid0000-0001-7904-883X
dc.contributor.orcid0000-0002-1953-7735
dc.contributor.orcid0000-0002-5956-8755
dc.contributor.researcheridABI-6078-2020
dc.contributor.researcheridAAP-9988-2020
dc.contributor.researcheridAAH-1656-2021
dc.contributor.researcheridGWV-3548-2022
dc.contributor.researcheridAAH-3843-2020
dc.contributor.researcheridF-8554-2017
dc.contributor.researcheridAAH-1420-2021
dc.contributor.scopusid57189387392
dc.contributor.scopusid57189380840
dc.contributor.scopusid6506587942
dc.contributor.scopusid55665145000
dc.contributor.scopusid6603411305
dc.contributor.scopusid6508156530
dc.contributor.scopusid23037226400
dc.contributor.scopusid6602965754
dc.contributor.scopusid57189390647
dc.contributor.scopusid55253485700
dc.contributor.scopusid25650627600
dc.contributor.scopusid56689608500
dc.date.accessioned2022-12-12T12:02:03Z
dc.date.available2022-12-12T12:02:03Z
dc.date.issued2016-05-11
dc.description.abstractProphylactic therapy response varies in migraine patients. The present study investigated the relationship between the resistance to the drugs commonly used in prophylactic therapy and the possible polymorphic variants of proteins involved in the metabolism of these drugs. Migraine patients with the MDR1 3435TT genotype exhibited a better treatment response to topiramate than migraine patients with the CC and CT genotypes (p = 0.020). The MDR1 C3435T polymorphism was also found to be a higher risk factor for topiramate treatment failure in a comparison of the number of days with migraine (beta(2) = 1.152, p = 0.015). However, there was no significant relationship between the treatment response to topiramate and either the CYP2D6 or CYP2C19 polymorphism, and there were no significant correlations between the treatment responses to amitriptyline, propranolol, and valproic acid and the MDR1, CYP2D6 and CYP2C19 gene polymorphisms. This is the first study to investigate the effect of the polymorphic variants on prophylactic therapy response in migraine patients.
dc.identifier.citationAtasayar, G. vd. (2016). "Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response". Journal of the Neurological Sciences, 366, 149-154.
dc.identifier.endpage154
dc.identifier.issn0022-510X
dc.identifier.issn1878-5883
dc.identifier.pubmed27288795
dc.identifier.scopus2-s2.0-84969944998
dc.identifier.startpage149
dc.identifier.urihttps://doi.org/10.1016/j.jns.2016.05.019
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0022510X16302787
dc.identifier.urihttp://hdl.handle.net/11452/29826
dc.identifier.volume366
dc.identifier.wos000379105400030
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherElsevier
dc.relation.journalJournal of the Neurological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNeurosciences & neurology
dc.subjectMigraine
dc.subjectProphylactic therapy response
dc.subjectMDR1
dc.subjectPolymorphism
dc.subjectMultidrug-resistance
dc.subjectC3435t polymorphism
dc.subjectCytochrome-P450
dc.subjectFrequency
dc.subjectAlleles
dc.subjectPharmacogenetics
dc.subjectPhenotype
dc.subjectGenotype
dc.subject2C19
dc.subject2D6
dc.subject.emtreeAmitriptyline
dc.subject.emtreeCytochrome P450 2C19
dc.subject.emtreeCytochrome P450 2D6
dc.subject.emtreeGenomic DNA
dc.subject.emtreeMultidrug resistance protein 1
dc.subject.emtreePropranolol
dc.subject.emtreeTopiramate
dc.subject.emtreeValproic acid
dc.subject.emtreeABCB1 protein, human
dc.subject.emtreeCentral nervous system agents
dc.subject.emtreeCYP2C19 protein, human
dc.subject.emtreeCytochrome P450 2C19
dc.subject.emtreeCytochrome P450 2D6
dc.subject.emtreeFructose
dc.subject.emtreeMultidrug resistance protein
dc.subject.emtreeTopiramate
dc.subject.emtreeAdult
dc.subject.emtreeAged
dc.subject.emtreeArticle
dc.subject.emtreeDNA polymorphism
dc.subject.emtreeFemale
dc.subject.emtreeGene frequency
dc.subject.emtreeGenetic association
dc.subject.emtreeGenotype
dc.subject.emtreeHuman
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMigraine
dc.subject.emtreeMigraine with aura
dc.subject.emtreeMigraine without aura
dc.subject.emtreeMonotherapy
dc.subject.emtreePriority journal
dc.subject.emtreeProphylaxis
dc.subject.emtreeTreatment response
dc.subject.emtreeAnalogs and derivatives
dc.subject.emtreeDrug resistance
dc.subject.emtreeGenetic association study
dc.subject.emtreeGenetic polymorphism
dc.subject.emtreeGenetics
dc.subject.emtreeMigraine disorders
dc.subject.emtreeRisk factor
dc.subject.emtreeTreatment outcome
dc.subject.meshAdult
dc.subject.meshAmitriptyline
dc.subject.meshCentral nervous system agents
dc.subject.meshCytochrome P-450 CYP2C19
dc.subject.meshCytochrome P-450 CYP2D6
dc.subject.meshDrug resistance
dc.subject.meshFemale
dc.subject.meshFructose
dc.subject.meshGene frequency
dc.subject.meshGenetic association studies
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMigraine disorders
dc.subject.meshP-glycoproteins
dc.subject.meshPolymorphism, genetic
dc.subject.meshPropranolol
dc.subject.meshRisk factors
dc.subject.meshTreatment outcome
dc.subject.meshValproic acid
dc.subject.scopusDrug Resistant Epilepsy; Epilepsy; Carbamazepine
dc.subject.wosClinical neurology
dc.subject.wosNeurosciences
dc.titleAssociation of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response
dc.typeArticle
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Nöroloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Tıbbi Biyoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Biyoistatistik Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: